Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Prim. 2017;3:17009.

Article  PubMed  Google Scholar 

Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl J Med. 2015;373:1814–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl J Med. 2021;384:829–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buil-Bruna N, López-Picazo J-M, Martín-Algarra S, Trocóniz IF. Bringing model-based prediction to oncology clinical practice: a review of pharmacometrics principles and applications. Oncologist. 2016;21:220–32.

Article  PubMed  Google Scholar 

Schmidinger M, Danesi R, Jones R, McDermott R, Pyle L, Rini B, et al. Individualized dosing with axitinib: rationale and practical guidance. Future Oncol Lond Engl. 2018;14:861–75.

Article  CAS  Google Scholar 

Lacy S, Nielsen J, Yang B, Miles D, Nguyen L, Hutmacher M. Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma. Cancer Chemother Pharm. 2018;81:1061–70.

Article  CAS  Google Scholar 

Castellano D, Pablo Maroto J, Benzaghou F, Taguieva N, Nguyen L, Clary DO, et al. Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. Cancer Treat Rev. 2020;89:102062.

Article  CAS  PubMed  Google Scholar 

Krens SD, van Erp NP, Groenland SL, Moes DJAR, Mulder SF, Desar IME, et al. Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer. BMC Cancer. 2022;22:228.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cerbone L, Combarel D, Geraud A, Auclin E, Foulon S, Alves Costa Silva C, et al. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO Open. 2021;6:100312.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lacy S, Yang B, Nielsen J, Miles D, Nguyen L, Hutmacher M. A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types. Cancer Chemother Pharm. 2018;81:1071–82.

Article  CAS  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 1990. 2009;45:228–47.

CAS  Google Scholar 

Lacy SA, Miles DR, Nguyen LT. Clinical pharmacokinetics and pharmacodynamics of cabozantinib. Clin Pharmacokinet. 2017;56:477–91.

Article  PubMed  Google Scholar 

Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:917–27.

Article  CAS  PubMed  Google Scholar 

Albiges L, Fléchon A, Chevreau C, Topart D, Gravis G, Oudard S, et al. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: results from the CABOREAL Early Access Program. Eur J Cancer Oxf Engl 1990. 2021;142:102–11.

CAS  Google Scholar 

Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharm. 2021;77:441–64.

Article  Google Scholar 

Puisset F, Mseddi M, Mourey L, Pouessel D, Blanchet B, Chatelut E, et al. Therapeutic drug monitoring of tyrosine kinase inhibitors in the treatment of advanced renal cancer. Cancers. 2023;15:313.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gan CL, Dudani S, Wells JC, Donskov F, Pal SK, Dizman N, et al. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Cancer Med. 2021;10:1212–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krens SD, van Boxtel W, Uijen MJM, Jansman FGA, Desar IME, Mulder SF, et al. Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer. Int J Cancer. 2022;150:308–16.

Article  CAS  PubMed  Google Scholar 

Tran BD, Li J, Ly N, Faggioni R, Roskos L. Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma. Cancer Chemother Pharm. 2023;91:179–89.

Article  CAS  Google Scholar 

Corianò M, Giannarelli D, Scartabellati G, De Giorgi U, Brighi N, Fornarini G, et al. Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome? Expert Rev Anticancer Ther. 2023;23:545–54.

Article  PubMed  Google Scholar 

Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, et al. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest N. Drugs. 2012;30:2046–9.

Article  CAS  Google Scholar 

Ozbey AC, Combarel D, Poinsignon V, Lovera C, Saada E, Mir O, et al. Population pharmacokinetic analysis of pazopanib in patients and determination of target AUC. Pharm Basel Switz. 2021;14:927.

CAS  Google Scholar 

Sharma A, Elias R, Christie A, Williams NS, Pedrosa I, Bjarnason GA, et al. Extended disease control with unconventional cabozantinib dose increase in metastatic renal cell carcinoma. Kidney Cancer Clifton Va. 2022;6:69–79.

Article  CAS  PubMed  Google Scholar 

Mir O, Touati N, Lia M, Litière S, Le Cesne A, Sleijfer S, et al. Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043/62072 trials. Clin Cancer Res J Am Assoc Cancer Res. 2019;25:1479–85.

Article  CAS  Google Scholar 

Ha VH, Ngo M, Chu MP, Ghosh S, Sawyer MB, Chambers CR. Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer? J Oncol Pharm Pr Publ Int Soc Oncol Pharm Pr. 2015;21:194–200.

CAS  Google Scholar 

Nguyen L, Holland J, Mamelok R, Laberge M-K, Grenier J, Swearingen D, et al. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. J Clin Pharm. 2015;55:1293–302.

Article  CAS  Google Scholar 

Rassy E, Cerbone L, Auclin E, Benchimoll-Zouari A, Flippot R, Alves Costa Silva C, et al. The effect of concomitant proton pump inhibitor and cabozantinib on the outcomes of patients with metastatic renal cell carcinoma. Oncologist. 2021;26:389–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buti S, Tommasi C, Scartabellati G, De Giorgi U, Brighi N, Rebuzzi SE, et al. The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. Anticancer Drugs. 2023;34:178–86.

Article  CAS  PubMed  Google Scholar 

Lee C-H, Shen M-C, Tsai M-J, Chang J-S, Huang Y-B, Yang Y-H, et al. Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib. Sci Rep. 2022;12:7002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McGregor B, Mortazavi A, Cordes L, Salabao C, Vandlik S, Apolo AB. Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: a review. Cancer Treat Rev. 2022;103:102333.

Article  CAS  PubMed  Google Scholar